Pfizer was Palvella Therapeutics’s largest revenue line in fiscal 2023, bringing in $15.13M of $42.81M (35%).
| Counterparty Name | FY 2009 | FY 2010 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2021 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astra Zeneca A B | $13.00M | $18.92M | — | $8.40M | |||||||||
| Astrazeneca | — | — | — | — | |||||||||
| Seagen | — | — | — | — | |||||||||
| Seattle Genetics | — | — | — | — | |||||||||
| Pfizer | — | — | $8.29M | $15.13M | |||||||||
| Allergan Inc | — | — | — | — | |||||||||
| Genentech | — | $1.95M | $3.14M | $12.70M | |||||||||
| Les Laboratoires Servier & Institut De Recherches Internationales Servier | — | $4.07M | — | $4.10M | |||||||||
| Servier | — | — | — | — | |||||||||
| Sanofi | — | — | — | — | |||||||||
| Boston Pharmaceuticals | — | $5.71M | — | $2.48M | |||||||||
| Roche | — | — | — | — | |||||||||
| Other | — | — | — | — | |||||||||
| Collaboration Partner One | — | — | — | — | |||||||||
| Seattle Genetics Inc | — | $768.00K | — | — | |||||||||
| Collaboration Partner Two | — | — | — | — | |||||||||
| Government Grant | — | — | — | — | |||||||||
| Total | $13.00M | $31.42M | $11.43M | $42.81M |
Palvella Therapeutics brought in $42.81M from its five revenue lines in fiscal 2023, the year ended December 31, 2023. Palvella Therapeutics regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $11.43M. Pfizer was the largest at $15.13M (35.4%), ahead of Genentech at $12.70M (29.7%) and Astra Zeneca A B at $8.40M (19.6%). The other two revenue lines brought in $6.58M combined.
Compared with fiscal 2022, Genentech grew 304.5% to $12.70M and Pfizer grew 82.6% to $15.13M.
Palvella Therapeutics began breaking out Pfizer in fiscal 2022, when it brought in $8.29M. Palvella Therapeutics stopped reporting Seattle Genetics Inc as a separate revenue line after fiscal 2021, when it brought in $768.00K.
Collaboration Revenue was Palvella Therapeutics’s largest revenue line in fiscal 2019, bringing in $25.80M of $46.28M (56%).
| Accounting Standards Update | FY 2019 |
|---|---|
| Collaboration Revenue | $25.80M |
| Customer Revenue | $20.48M |
| Total | $46.28M |
Palvella Therapeutics brought in $46.28M from its two revenue lines in fiscal 2019, the year ended December 31, 2019. That is less than the $55.23M it reports by restatement, so these revenue lines do not cover all of its revenue. Collaboration Revenue was the largest at $25.80M (55.7%), ahead of Customer Revenue at $20.48M (44.3%).
As Reported Pre-Adoption was Palvella Therapeutics’s largest revenue line in fiscal 2019, bringing in $43.65M of $55.23M (79%).
| Restatement | FY 2019 |
|---|---|
| As Reported Pre-Adoption | $43.65M |
| Asc 808 Adoption Adjustment | $11.58M |
| Total | $55.23M |
Palvella Therapeutics brought in $55.23M from its two revenue lines in fiscal 2019, the year ended December 31, 2019. As Reported Pre-Adoption was the largest at $43.65M (79.0%), ahead of Asc 808 Adoption Adjustment at $11.58M (21.0%).
Palvella Therapeutics (PVLA) reports its revenue by counterparty name, by accounting standards update and by restatement. In fiscal 2023, Pfizer was its largest revenue line, bringing in $15.13M (35.4% of the total), followed by Genentech at $12.70M (29.7%).
Pfizer was Palvella Therapeutics' largest revenue line in fiscal 2023, bringing in $15.13M, or 35.4% of the $42.81M total across its five revenue lines.
Every figure comes from Palvella Therapeutics' annual financial filings, as reported. Each line keeps the name Palvella Therapeutics gives it, and years follow its fiscal calendar.
Palvella Therapeutics' revenue by counterparty name goes back to fiscal 2009, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.